Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients
MT218-002 (primary)
NCI-2024-04399
Summary
This phase 1b open label, dose-escalating investigation study is to evaluate the dose
dependent initial efficacy of the use of MT218 injection for biomarker targeted MR
molecular imaging (MRMI) of prostate cancer in patients scheduled for radical
prostatectomy.
Objectives
Phase 1b open label, single-arm, dose-escalating investigation of safety and efficacy of
a gadolinium (Gd) and peptide based MRI contrast agent (MT218) as an extradomain-B
fibronectin (EDB-FN) targeted molecular MR contrast agent to detect aggressive prostate
cancer with comparison of its results with the standard-of-care mutliparametic MRI
(mpMRI) and PSMA PET/CT and histopathology validation in preprostatectomy patients
diagnosed with prostate cancer in their clinical care.
Eligibility
- Inclusion criteria
- Male subjects aged >18 years.
- Patients with confirmed Gleason score of 8 - 10 prostate cancer, had at least one
prostate mpMRI and one prostate biopsy.
- Ability to lie still for MRI scanning.
- Patients must be able to provide written informed consent.
- Glomerular filtration rate (GFR) > 60 mL/min within a 30 days of the research MRI.
Key exclusion criteria
- Any diagnosis of active acute, chronic, or sub-chronic kidney or liver disease.
- Documented acute prostatitis, symptomatic or severe benign prostatic hyperplasia
(BPH) or urinary tract infections.
- Patients with uncontrolled diabetes or hypertension.
- Patients with active non-prostate malignancy.
- Patients with contraindications for MRI including implantable pace makers, cochlear
implants.
- Patients with uni- or bilateral hip prosthesis.
- Subjects with other significant medical conditions that would create unacceptable
operative risk, compromise retention on study or compromise study related
assessments.
- Major surgery within 4 weeks prior to entry on this study or patients who have not
recovered from side effects of such therapy.
- Prostate biopsy within 4 weeks prior to entry on this study in which inflammation
might affect MRI result.
- Subjects who received or will receive any other MRI contrast agent within 48 hours
prior to MT218 injection or up to 24 hours after MT218 injection.
- Is determined by the investigator that the patient is clinically unsuitable for the
study.
- Is incapable of understanding the language in which the information for the patient
is given.
- Participation in a concurrent clinical trial or in another trial within the past 30
days.
Treatment Sites in Georgia
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials.